FR13C0029I2 - Compositions pour le traitement de troubles gastro-intestinaux - Google Patents

Compositions pour le traitement de troubles gastro-intestinaux

Info

Publication number
FR13C0029I2
FR13C0029I2 FR13C0029C FR13C0029C FR13C0029I2 FR 13C0029 I2 FR13C0029 I2 FR 13C0029I2 FR 13C0029 C FR13C0029 C FR 13C0029C FR 13C0029 C FR13C0029 C FR 13C0029C FR 13C0029 I2 FR13C0029 I2 FR 13C0029I2
Authority
FR
France
Prior art keywords
compositions
treatment
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0029C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of FR13C0029I1 publication Critical patent/FR13C0029I1/fr
Application granted granted Critical
Publication of FR13C0029I2 publication Critical patent/FR13C0029I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
FR13C0029C 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux Active FR13C0029I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
PCT/US2004/002390 WO2004069165A2 (fr) 2003-01-28 2004-01-28 Procedes et compositions pour le traitement de troubles gastro-intestinaux

Publications (2)

Publication Number Publication Date
FR13C0029I1 FR13C0029I1 (fr) 2013-07-05
FR13C0029I2 true FR13C0029I2 (fr) 2024-04-19

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0029C Active FR13C0029I2 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastro-intestinaux
FR13C0030C Active FR13C0030I1 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0030C Active FR13C0030I1 (fr) 2003-01-28 2013-05-23 Compositions pour le traitement de troubles gastrointestinaux

Country Status (28)

Country Link
US (3) US20040266989A1 (fr)
EP (3) EP1594517B1 (fr)
JP (3) JP4584911B2 (fr)
KR (2) KR101227626B1 (fr)
CN (2) CN100589839C (fr)
AT (2) ATE477268T1 (fr)
AU (2) AU2004210161B2 (fr)
BE (1) BE2013C032I2 (fr)
BR (2) BR122018074353B8 (fr)
CA (1) CA2514507C (fr)
CY (5) CY1110905T1 (fr)
DE (2) DE602004007105T2 (fr)
DK (3) DK1911763T3 (fr)
ES (3) ES2387848T3 (fr)
FR (2) FR13C0029I2 (fr)
HU (1) HUS1300022I1 (fr)
IL (2) IL169863A (fr)
LT (1) LTC1594517I2 (fr)
LU (2) LU92200I2 (fr)
MX (1) MXPA05008097A (fr)
NL (1) NL300593I2 (fr)
NO (3) NO334112B1 (fr)
NZ (2) NZ570134A (fr)
PT (3) PT1911763E (fr)
RU (2) RU2353383C2 (fr)
SG (2) SG192300A1 (fr)
SI (3) SI2246360T1 (fr)
WO (1) WO2004069165A2 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
ATE477268T1 (de) * 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
WO2005115412A2 (fr) * 2004-05-25 2005-12-08 University Of Georgia Research Foundation, Inc. Compositions et procedes de modulation d'une reponse immunitaire
JPWO2006046746A1 (ja) * 2004-10-26 2008-05-22 味の素株式会社 内臓痛予防・治療剤
WO2007022531A2 (fr) * 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux
CN105381453B9 (zh) 2005-09-29 2019-01-11 益普生制药股份有限公司 用于刺激胃肠运动性的组合物和方法
EP1996218A4 (fr) * 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc Méthodes et compositions servant au traitement de troubles gastro-intestinaux
EP2650303A1 (fr) * 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
RU2009144972A (ru) * 2007-05-04 2011-06-10 Айронвуд Фармасьютикалз, Инк. (Us) Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2296685B1 (fr) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010005515A2 (fr) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Procédés d’expression de protéines
CA2730603C (fr) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
US20120213846A1 (en) * 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
CA2743172A1 (fr) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Forme cristalline de la linaclotide
AU2009322285B2 (en) * 2008-12-03 2016-07-28 Bausch Health Ireland Limited Formulations of guanylate cyclase C agonists and methods of use
WO2010115916A1 (fr) 2009-04-10 2010-10-14 F. Hoffmann-La Roche Ag Procédé d'isolement d'un peptide thérapeutique
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
PH12012500916B1 (en) 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
EP2509992B1 (fr) 2009-12-07 2015-10-14 Ironwood Pharmaceuticals, Inc. Traitement des troubles gastro-intestinaux
WO2011103311A2 (fr) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Traitements de troubles gastro-intestinaux
WO2011145062A1 (fr) 2010-05-21 2011-11-24 Link Research & Grants Corporation Traitement des acouphènes et de dysfonctions auditives apparentées
WO2011156453A2 (fr) 2010-06-09 2011-12-15 Combimab, Inc. Peptides thérapeutiques
HRP20192207T1 (hr) 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
EP2621509A4 (fr) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9650417B2 (en) 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155114A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Nouveaux dérivés d'uroguanyline et leur utilisation pour le traitement des troubles gastro-intestinaux
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z (ro) * 2011-07-07 2012-09-30 Elvira Andon Metoda de tratament al colitei ulceroase nespecifice acute
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
WO2014088623A1 (fr) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Compositions de linaclotide
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
EP2950803A1 (fr) 2013-01-30 2015-12-09 Sandoz AG Forme cristalline de linaclotide
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
HUE061954T2 (hu) * 2015-05-01 2023-09-28 Ironwood Pharmaceuticals Inc Vastagbél tisztítására és gyomor-bélrendszeri rendellenességek kezelésére szolgáló készítmények
WO2017160938A1 (fr) * 2016-03-15 2017-09-21 The Regents Of The University Of California Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine α8β1
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
WO2020082168A1 (fr) * 2018-10-23 2020-04-30 Abk Biomedical Incorporated Dispositif d'administration
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
EP4469468A1 (fr) 2022-01-28 2024-12-04 Fresenius Kabi iPSUM S.r.l. Procédé de préparation de linaclotide
WO2025207484A1 (fr) * 2024-03-25 2025-10-02 Merveille.Ai Utilisation d'aprépitant et d'un dipeptide cyclique pour le contrôle du poids

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73628A (en) * 1868-01-21 mitchell
US232013A (en) * 1880-09-07 Henry h
US266989A (en) * 1882-11-07 Automatic fire
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US258687A (en) * 1882-05-30 Grain-binder
US32684A (en) * 1861-07-02 Stump-extkactob
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (fr) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (fr) 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
ATE165977T1 (de) 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
JPH08505395A (ja) 1993-01-06 1996-06-11 キナートン リミティド 生物分解性ポリエステルと生物活性ポリペプチドのイオン分子結合体
US5395490A (en) 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
ES2216004T3 (es) * 1993-10-26 2004-10-16 Thomas Jefferson University Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas.
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
ES2194998T3 (es) 1995-06-27 2003-12-01 Elan Pharm Inc Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
DE69634416T2 (de) 1995-11-24 2005-12-29 Glaxosmithkline S.P.A. Chinolin-derivate
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
JP3155013B2 (ja) 1996-04-23 2001-04-09 キナートン・リミテッド 酸性ポリ乳酸ポリマー
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DK0975347T3 (da) 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
ATE273996T1 (de) 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
WO2001000221A2 (fr) 1999-06-23 2001-01-04 Institut Pasteur Methodes therapeutiques et compositions pour le traitement de troubles interpersonnels et du comportement
ES2209948T3 (es) 1999-08-18 2004-07-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Formulacion de un peptico de liberacion sostenida.
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
WO2001025266A1 (fr) 1999-10-06 2001-04-12 Pharmacia Corporation Uroguanyline, anticancereux intestinal
PT1225897E (pt) 1999-11-01 2005-01-31 John Rhodes Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU3580001A (en) 2000-03-01 2001-09-12 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
EP1216707B1 (fr) 2000-12-22 2005-02-09 Institut Pasteur Méthode de criblage pour des ligands capables de se lier spécifiquement au site de liaison du NEP pour le pentapeptide QHNPR
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
JP4206272B2 (ja) * 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
EP1451211A2 (fr) 2001-03-30 2004-09-01 University of Copenhagen Compositions et procedes de modulation de l'activite du recepteur signalant la guanylyl cylclase et de traitement de la maladie de meniere
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
AU2002316771A1 (en) 2001-06-05 2002-12-16 Yalcin Cetin Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (fr) 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
CA2479350A1 (fr) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Inhibiteurs de recaptage de 5-ht pour le traitement de syndromes de la douleur viscerale
CN100411618C (zh) 2002-05-17 2008-08-20 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) * 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (fr) 2003-02-10 2010-09-08 Univ Jefferson Utilisation de ligands gcc
WO2007022531A2 (fr) * 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
SG168407A1 (en) 2011-02-28
WO2004069165A3 (fr) 2005-03-17
HUS1300022I1 (hu) 2019-11-28
EP1594517A2 (fr) 2005-11-16
DK1594517T3 (da) 2007-10-29
RU2014153593A (ru) 2016-07-20
PT1594517E (pt) 2007-07-20
NO20130460L (no) 2005-10-26
CA2514507C (fr) 2012-03-20
ES2350123T3 (es) 2011-01-18
AU2009235993A1 (en) 2009-11-26
SG192300A1 (en) 2013-08-30
NZ541595A (en) 2008-08-29
CA2514507A1 (fr) 2004-08-19
CY1113217T1 (el) 2016-04-13
EP2246360A1 (fr) 2010-11-03
BRPI0407071B8 (pt) 2021-05-25
CY2013022I1 (el) 2020-05-29
JP5563384B2 (ja) 2014-07-30
JP4584911B2 (ja) 2010-11-24
EP1911763A2 (fr) 2008-04-16
CY2013021I2 (el) 2025-07-04
NO336768B1 (no) 2015-11-02
JP2013116910A (ja) 2013-06-13
US20110124583A1 (en) 2011-05-26
RU2005127058A (ru) 2006-03-10
EP1911763A3 (fr) 2008-06-25
AU2004210161B2 (en) 2009-11-26
HK1078768A1 (en) 2006-03-24
NO20053864L (no) 2005-10-26
NZ570134A (en) 2010-02-26
IL169863A (en) 2012-10-31
DK1911763T3 (da) 2010-11-15
NO2014013I2 (no) 2014-05-21
AU2009235993B2 (en) 2013-07-04
WO2004069165A2 (fr) 2004-08-19
NO2014013I1 (no) 2014-06-02
PT1911763E (pt) 2010-11-18
US7704947B2 (en) 2010-04-27
US20090005534A1 (en) 2009-01-01
BE2013C032I2 (fr) 2023-08-22
US8080526B2 (en) 2011-12-20
EP1594517A4 (fr) 2006-03-29
SI1911763T1 (sl) 2010-11-30
US20040266989A1 (en) 2004-12-30
JP2006516631A (ja) 2006-07-06
DE602004007105D1 (de) 2007-08-02
BR122018074353B1 (pt) 2019-07-16
RU2008147983A (ru) 2010-06-10
IL221380A0 (en) 2012-09-24
CN101787073A (zh) 2010-07-28
RU2763796C2 (ru) 2022-01-11
CN1795007A (zh) 2006-06-28
CY1110905T1 (el) 2015-06-10
NL300593I2 (nl) 2020-04-15
KR20050106404A (ko) 2005-11-09
EP1911763B1 (fr) 2010-08-11
MXPA05008097A (es) 2006-02-08
BRPI0407071B1 (pt) 2019-02-12
LU92201I2 (fr) 2013-11-22
ES2285417T3 (es) 2007-11-16
FR13C0029I1 (fr) 2013-07-05
JP5748791B2 (ja) 2015-07-15
LU92200I2 (fr) 2024-03-21
KR101227627B1 (ko) 2013-01-31
ES2387848T3 (es) 2012-10-02
EP2246360B1 (fr) 2012-06-27
SI1594517T1 (sl) 2007-10-31
RU2353383C2 (ru) 2009-04-27
EP1594517B1 (fr) 2007-06-20
NO334112B1 (no) 2013-12-09
JP2010222377A (ja) 2010-10-07
ATE365174T1 (de) 2007-07-15
LU92200I1 (fr) 2020-06-02
SI2246360T1 (sl) 2012-10-30
ATE477268T1 (de) 2010-08-15
KR101227626B1 (ko) 2013-02-01
DE602004007105T2 (de) 2008-02-28
DK2246360T3 (da) 2012-08-13
NO20053864D0 (no) 2005-08-18
CN101787073B (zh) 2013-12-25
LTC1594517I2 (lt) 2020-03-10
KR20110114682A (ko) 2011-10-19
DE602004028678D1 (de) 2010-09-23
CY2013021I1 (el) 2020-05-29
NL300593I1 (nl) 2015-10-21
PT2246360E (pt) 2012-08-31
FR13C0030I1 (fr) 2013-07-05
RU2014153593A3 (fr) 2018-08-06
BRPI0407071A (pt) 2006-01-24
CN100589839C (zh) 2010-02-17
BR122018074353B8 (pt) 2023-05-02
AU2004210161A1 (en) 2004-08-19
CY1111058T1 (el) 2015-06-11
RU2543350C2 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
FR13C0029I1 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
EP1881823A4 (fr) Compositions et procedes pour le traitement des troubles oculaires
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
EP1628530A4 (fr) Procedes et compositions pour la prevention et le traitement de la sepsie
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
EP1773226A4 (fr) Dispositifs électriques pour le traitement de défauts anatomiques
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
EP1727530A4 (fr) Formulations topiques pour le traitement d'etats dermatologiques
MA29098B1 (fr) Compositions pour le traitement du vhc
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
EP1644039A4 (fr) Compositions et procedes pour le traitement des troubles lies a la coagulation
EP2056848A4 (fr) Utilisation d'extraits pour le traitement de troubles viraux
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1940441A4 (fr) Compositions et methodes de traitement de troubles gastro-intestinaux
FR13C0044I2 (fr) Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
EP2307011A4 (fr) Utilisation d'isoindoles pour le traitement de troubles neurocomportementaux
EP1951261A4 (fr) Préparations et méthodes pour le traitement de troubles inflammatoires
EP1804787A4 (fr) Composition flavonoide pour le traitement des maladies bucco-dentaires
EP1581243A4 (fr) Lactoferrine orale pour le traitement des sepsies
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
EP1933813A4 (fr) Liposomes de sphingomyeline pour le traitement de troubles de vessie hyperactive